nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—CYP2C8—Spironolactone—dilated cardiomyopathy	0.216	0.409	CbGbCtD
Buprenorphine—ABCB1—Lisinopril—dilated cardiomyopathy	0.166	0.314	CbGbCtD
Buprenorphine—ABCB1—Spironolactone—dilated cardiomyopathy	0.146	0.277	CbGbCtD
Buprenorphine—Hypotensive—Furosemide—dilated cardiomyopathy	0.0116	0.0318	CcSEcCtD
Buprenorphine—Cerebration impaired—Furosemide—dilated cardiomyopathy	0.00721	0.0197	CcSEcCtD
Buprenorphine—Appetite absent—Lisinopril—dilated cardiomyopathy	0.00639	0.0175	CcSEcCtD
Buprenorphine—Apathy—Furosemide—dilated cardiomyopathy	0.00593	0.0162	CcSEcCtD
Buprenorphine—Flat affect—Furosemide—dilated cardiomyopathy	0.00588	0.0161	CcSEcCtD
Buprenorphine—Lethargy—Spironolactone—dilated cardiomyopathy	0.00577	0.0158	CcSEcCtD
Buprenorphine—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.00509	0.0139	CcSEcCtD
Buprenorphine—Disturbance in attention—Furosemide—dilated cardiomyopathy	0.00489	0.0134	CcSEcCtD
Buprenorphine—Heartburn—Lisinopril—dilated cardiomyopathy	0.00462	0.0126	CcSEcCtD
Buprenorphine—Drug interaction—Furosemide—dilated cardiomyopathy	0.00457	0.0125	CcSEcCtD
Buprenorphine—Memory impairment—Lisinopril—dilated cardiomyopathy	0.00405	0.0111	CcSEcCtD
Buprenorphine—Mental disability—Furosemide—dilated cardiomyopathy	0.00368	0.0101	CcSEcCtD
Buprenorphine—Accidental injury—Lisinopril—dilated cardiomyopathy	0.00359	0.00984	CcSEcCtD
Buprenorphine—Drug interaction—Lisinopril—dilated cardiomyopathy	0.00343	0.00938	CcSEcCtD
Buprenorphine—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00327	0.00896	CcSEcCtD
Buprenorphine—Neck pain—Lisinopril—dilated cardiomyopathy	0.00322	0.00881	CcSEcCtD
Buprenorphine—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00322	0.00881	CcSEcCtD
Buprenorphine—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00316	0.00865	CcSEcCtD
Buprenorphine—Lethargy—Furosemide—dilated cardiomyopathy	0.00314	0.00859	CcSEcCtD
Buprenorphine—Wheezing—Lisinopril—dilated cardiomyopathy	0.00309	0.00845	CcSEcCtD
Buprenorphine—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.00309	0.00845	CcSEcCtD
Buprenorphine—Malaise—Spironolactone—dilated cardiomyopathy	0.00307	0.00841	CcSEcCtD
Buprenorphine—Urinary retention—Furosemide—dilated cardiomyopathy	0.00293	0.00801	CcSEcCtD
Buprenorphine—Discomfort—Spironolactone—dilated cardiomyopathy	0.00286	0.00784	CcSEcCtD
Buprenorphine—Dehydration—Furosemide—dilated cardiomyopathy	0.00286	0.00783	CcSEcCtD
Buprenorphine—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00281	0.00769	CcSEcCtD
Buprenorphine—Confusional state—Spironolactone—dilated cardiomyopathy	0.0028	0.00767	CcSEcCtD
Buprenorphine—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00278	0.00761	CcSEcCtD
Buprenorphine—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00277	0.00758	CcSEcCtD
Buprenorphine—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00271	0.00743	CcSEcCtD
Buprenorphine—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00268	0.00733	CcSEcCtD
Buprenorphine—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00267	0.0073	CcSEcCtD
Buprenorphine—Injury—Lisinopril—dilated cardiomyopathy	0.00251	0.00687	CcSEcCtD
Buprenorphine—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00249	0.00681	CcSEcCtD
Buprenorphine—Somnolence—Spironolactone—dilated cardiomyopathy	0.00247	0.00676	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.0024	0.00657	CcSEcCtD
Buprenorphine—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00231	0.00632	CcSEcCtD
Buprenorphine—Diplopia—Lisinopril—dilated cardiomyopathy	0.00231	0.00632	CcSEcCtD
Buprenorphine—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00231	0.00632	CcSEcCtD
Buprenorphine—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00229	0.00627	CcSEcCtD
Buprenorphine—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00229	0.00627	CcSEcCtD
Buprenorphine—Sweating—Furosemide—dilated cardiomyopathy	0.00227	0.00622	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00224	0.00614	CcSEcCtD
Buprenorphine—Face oedema—Lisinopril—dilated cardiomyopathy	0.00223	0.0061	CcSEcCtD
Buprenorphine—Urticaria—Spironolactone—dilated cardiomyopathy	0.00221	0.00604	CcSEcCtD
Buprenorphine—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.0022	0.00601	CcSEcCtD
Buprenorphine—Dehydration—Lisinopril—dilated cardiomyopathy	0.00215	0.00588	CcSEcCtD
Buprenorphine—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00211	0.00577	CcSEcCtD
Buprenorphine—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.0021	0.00575	CcSEcCtD
Buprenorphine—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00209	0.00571	CcSEcCtD
Buprenorphine—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00209	0.00571	CcSEcCtD
Buprenorphine—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00208	0.00569	CcSEcCtD
Buprenorphine—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00206	0.00565	CcSEcCtD
Buprenorphine—Visual impairment—Furosemide—dilated cardiomyopathy	0.00205	0.00561	CcSEcCtD
Buprenorphine—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00205	0.0056	CcSEcCtD
Buprenorphine—Asthma—Lisinopril—dilated cardiomyopathy	0.00199	0.00546	CcSEcCtD
Buprenorphine—Influenza—Lisinopril—dilated cardiomyopathy	0.00199	0.00546	CcSEcCtD
Buprenorphine—Eye disorder—Furosemide—dilated cardiomyopathy	0.00199	0.00544	CcSEcCtD
Buprenorphine—Tinnitus—Furosemide—dilated cardiomyopathy	0.00198	0.00543	CcSEcCtD
Buprenorphine—Pruritus—Spironolactone—dilated cardiomyopathy	0.00197	0.00538	CcSEcCtD
Buprenorphine—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.00196	0.00537	CcSEcCtD
Buprenorphine—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00194	0.00532	CcSEcCtD
Buprenorphine—Angiopathy—Furosemide—dilated cardiomyopathy	0.00193	0.00529	CcSEcCtD
Buprenorphine—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00192	0.00526	CcSEcCtD
Buprenorphine—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00192	0.00525	CcSEcCtD
Buprenorphine—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.0019	0.0052	CcSEcCtD
Buprenorphine—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00185	0.00507	CcSEcCtD
Buprenorphine—Malnutrition—Furosemide—dilated cardiomyopathy	0.00185	0.00507	CcSEcCtD
Buprenorphine—Erythema—Furosemide—dilated cardiomyopathy	0.00185	0.00507	CcSEcCtD
Buprenorphine—Dizziness—Spironolactone—dilated cardiomyopathy	0.00184	0.00503	CcSEcCtD
Buprenorphine—Flatulence—Furosemide—dilated cardiomyopathy	0.00183	0.005	CcSEcCtD
Buprenorphine—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00181	0.00497	CcSEcCtD
Buprenorphine—Weight decreased—Lisinopril—dilated cardiomyopathy	0.0018	0.00494	CcSEcCtD
Buprenorphine—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00178	0.00488	CcSEcCtD
Buprenorphine—Depression—Lisinopril—dilated cardiomyopathy	0.00177	0.00485	CcSEcCtD
Buprenorphine—Vomiting—Spironolactone—dilated cardiomyopathy	0.00177	0.00484	CcSEcCtD
Buprenorphine—Rash—Spironolactone—dilated cardiomyopathy	0.00175	0.0048	CcSEcCtD
Buprenorphine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00175	0.00479	CcSEcCtD
Buprenorphine—Vision blurred—Furosemide—dilated cardiomyopathy	0.00175	0.00478	CcSEcCtD
Buprenorphine—Headache—Spironolactone—dilated cardiomyopathy	0.00174	0.00477	CcSEcCtD
Buprenorphine—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00173	0.00473	CcSEcCtD
Buprenorphine—Sweating—Lisinopril—dilated cardiomyopathy	0.00171	0.00467	CcSEcCtD
Buprenorphine—Agitation—Furosemide—dilated cardiomyopathy	0.0017	0.00466	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00168	0.0046	CcSEcCtD
Buprenorphine—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00167	0.00457	CcSEcCtD
Buprenorphine—Vertigo—Furosemide—dilated cardiomyopathy	0.00166	0.00456	CcSEcCtD
Buprenorphine—Nausea—Spironolactone—dilated cardiomyopathy	0.00165	0.00452	CcSEcCtD
Buprenorphine—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00163	0.00445	CcSEcCtD
Buprenorphine—Rhinitis—Lisinopril—dilated cardiomyopathy	0.0016	0.00438	CcSEcCtD
Buprenorphine—Hallucination—Lisinopril—dilated cardiomyopathy	0.00159	0.00435	CcSEcCtD
Buprenorphine—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00158	0.00434	CcSEcCtD
Buprenorphine—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00158	0.00432	CcSEcCtD
Buprenorphine—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00157	0.00431	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00157	0.00429	CcSEcCtD
Buprenorphine—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00157	0.00428	CcSEcCtD
Buprenorphine—Dry mouth—Furosemide—dilated cardiomyopathy	0.00154	0.00422	CcSEcCtD
Buprenorphine—Confusional state—Furosemide—dilated cardiomyopathy	0.00152	0.00417	CcSEcCtD
Buprenorphine—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00151	0.00414	CcSEcCtD
Buprenorphine—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00149	0.00408	CcSEcCtD
Buprenorphine—Shock—Furosemide—dilated cardiomyopathy	0.00149	0.00407	CcSEcCtD
Buprenorphine—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00148	0.00406	CcSEcCtD
Buprenorphine—Flushing—Lisinopril—dilated cardiomyopathy	0.00148	0.00406	CcSEcCtD
Buprenorphine—Skin disorder—Furosemide—dilated cardiomyopathy	0.00147	0.00402	CcSEcCtD
Buprenorphine—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00146	0.004	CcSEcCtD
Buprenorphine—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00145	0.00397	CcSEcCtD
Buprenorphine—Anorexia—Furosemide—dilated cardiomyopathy	0.00144	0.00394	CcSEcCtD
Buprenorphine—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00144	0.00394	CcSEcCtD
Buprenorphine—Chills—Lisinopril—dilated cardiomyopathy	0.00143	0.00392	CcSEcCtD
Buprenorphine—Hypotension—Furosemide—dilated cardiomyopathy	0.00141	0.00387	CcSEcCtD
Buprenorphine—Mental disorder—Lisinopril—dilated cardiomyopathy	0.0014	0.00383	CcSEcCtD
Buprenorphine—Erythema—Lisinopril—dilated cardiomyopathy	0.00139	0.0038	CcSEcCtD
Buprenorphine—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00139	0.0038	CcSEcCtD
Buprenorphine—Flatulence—Lisinopril—dilated cardiomyopathy	0.00137	0.00375	CcSEcCtD
Buprenorphine—Tension—Lisinopril—dilated cardiomyopathy	0.00136	0.00373	CcSEcCtD
Buprenorphine—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00136	0.00373	CcSEcCtD
Buprenorphine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00136	0.00372	CcSEcCtD
Buprenorphine—Nervousness—Lisinopril—dilated cardiomyopathy	0.00135	0.0037	CcSEcCtD
Buprenorphine—Back pain—Lisinopril—dilated cardiomyopathy	0.00134	0.00368	CcSEcCtD
Buprenorphine—Somnolence—Furosemide—dilated cardiomyopathy	0.00134	0.00368	CcSEcCtD
Buprenorphine—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00134	0.00366	CcSEcCtD
Buprenorphine—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00131	0.0036	CcSEcCtD
Buprenorphine—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00131	0.00359	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00131	0.00357	CcSEcCtD
Buprenorphine—Fatigue—Furosemide—dilated cardiomyopathy	0.0013	0.00357	CcSEcCtD
Buprenorphine—Tremor—Lisinopril—dilated cardiomyopathy	0.0013	0.00356	CcSEcCtD
Buprenorphine—Pain—Furosemide—dilated cardiomyopathy	0.00129	0.00354	CcSEcCtD
Buprenorphine—Constipation—Furosemide—dilated cardiomyopathy	0.00129	0.00354	CcSEcCtD
Buprenorphine—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00129	0.00353	CcSEcCtD
Buprenorphine—Angioedema—Lisinopril—dilated cardiomyopathy	0.00127	0.00348	CcSEcCtD
Buprenorphine—Malaise—Lisinopril—dilated cardiomyopathy	0.00125	0.00343	CcSEcCtD
Buprenorphine—Vertigo—Lisinopril—dilated cardiomyopathy	0.00125	0.00342	CcSEcCtD
Buprenorphine—Syncope—Lisinopril—dilated cardiomyopathy	0.00125	0.00341	CcSEcCtD
Buprenorphine—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00125	0.00341	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00124	0.00338	CcSEcCtD
Buprenorphine—Palpitations—Lisinopril—dilated cardiomyopathy	0.00123	0.00336	CcSEcCtD
Buprenorphine—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00122	0.00334	CcSEcCtD
Buprenorphine—Cough—Lisinopril—dilated cardiomyopathy	0.00121	0.00332	CcSEcCtD
Buprenorphine—Urticaria—Furosemide—dilated cardiomyopathy	0.0012	0.00329	CcSEcCtD
Buprenorphine—Abdominal pain—Furosemide—dilated cardiomyopathy	0.0012	0.00327	CcSEcCtD
Buprenorphine—Body temperature increased—Furosemide—dilated cardiomyopathy	0.0012	0.00327	CcSEcCtD
Buprenorphine—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00118	0.00324	CcSEcCtD
Buprenorphine—Chest pain—Lisinopril—dilated cardiomyopathy	0.00118	0.00324	CcSEcCtD
Buprenorphine—Myalgia—Lisinopril—dilated cardiomyopathy	0.00118	0.00324	CcSEcCtD
Buprenorphine—Anxiety—Lisinopril—dilated cardiomyopathy	0.00118	0.00323	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00118	0.00322	CcSEcCtD
Buprenorphine—Discomfort—Lisinopril—dilated cardiomyopathy	0.00117	0.0032	CcSEcCtD
Buprenorphine—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00116	0.00317	CcSEcCtD
Buprenorphine—Confusional state—Lisinopril—dilated cardiomyopathy	0.00114	0.00313	CcSEcCtD
Buprenorphine—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00113	0.00311	CcSEcCtD
Buprenorphine—Oedema—Lisinopril—dilated cardiomyopathy	0.00113	0.00311	CcSEcCtD
Buprenorphine—Infection—Lisinopril—dilated cardiomyopathy	0.00113	0.00308	CcSEcCtD
Buprenorphine—Shock—Lisinopril—dilated cardiomyopathy	0.00112	0.00305	CcSEcCtD
Buprenorphine—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00111	0.00305	CcSEcCtD
Buprenorphine—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00111	0.00303	CcSEcCtD
Buprenorphine—Skin disorder—Lisinopril—dilated cardiomyopathy	0.0011	0.00302	CcSEcCtD
Buprenorphine—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.0011	0.003	CcSEcCtD
Buprenorphine—Asthenia—Furosemide—dilated cardiomyopathy	0.00108	0.00297	CcSEcCtD
Buprenorphine—Anorexia—Lisinopril—dilated cardiomyopathy	0.00108	0.00296	CcSEcCtD
Buprenorphine—Pruritus—Furosemide—dilated cardiomyopathy	0.00107	0.00293	CcSEcCtD
Buprenorphine—Hypotension—Lisinopril—dilated cardiomyopathy	0.00106	0.0029	CcSEcCtD
Buprenorphine—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00103	0.00283	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00103	0.00283	CcSEcCtD
Buprenorphine—Insomnia—Lisinopril—dilated cardiomyopathy	0.00103	0.00281	CcSEcCtD
Buprenorphine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00102	0.00279	CcSEcCtD
Buprenorphine—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00101	0.00277	CcSEcCtD
Buprenorphine—Somnolence—Lisinopril—dilated cardiomyopathy	0.00101	0.00276	CcSEcCtD
Buprenorphine—Dizziness—Furosemide—dilated cardiomyopathy	0.001	0.00274	CcSEcCtD
Buprenorphine—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000999	0.00273	CcSEcCtD
Buprenorphine—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000986	0.0027	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000979	0.00268	CcSEcCtD
Buprenorphine—Fatigue—Lisinopril—dilated cardiomyopathy	0.000978	0.00268	CcSEcCtD
Buprenorphine—Pain—Lisinopril—dilated cardiomyopathy	0.00097	0.00266	CcSEcCtD
Buprenorphine—Constipation—Lisinopril—dilated cardiomyopathy	0.00097	0.00266	CcSEcCtD
Buprenorphine—Vomiting—Furosemide—dilated cardiomyopathy	0.000961	0.00263	CcSEcCtD
Buprenorphine—Rash—Furosemide—dilated cardiomyopathy	0.000953	0.00261	CcSEcCtD
Buprenorphine—Dermatitis—Furosemide—dilated cardiomyopathy	0.000952	0.00261	CcSEcCtD
Buprenorphine—Headache—Furosemide—dilated cardiomyopathy	0.000947	0.00259	CcSEcCtD
Buprenorphine—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000935	0.00256	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000928	0.00254	CcSEcCtD
Buprenorphine—Urticaria—Lisinopril—dilated cardiomyopathy	0.000901	0.00247	CcSEcCtD
Buprenorphine—Nausea—Furosemide—dilated cardiomyopathy	0.000898	0.00246	CcSEcCtD
Buprenorphine—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000897	0.00245	CcSEcCtD
Buprenorphine—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000897	0.00245	CcSEcCtD
Buprenorphine—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000836	0.00229	CcSEcCtD
Buprenorphine—Asthenia—Lisinopril—dilated cardiomyopathy	0.000814	0.00223	CcSEcCtD
Buprenorphine—Pruritus—Lisinopril—dilated cardiomyopathy	0.000803	0.0022	CcSEcCtD
Buprenorphine—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000776	0.00212	CcSEcCtD
Buprenorphine—Dizziness—Lisinopril—dilated cardiomyopathy	0.00075	0.00205	CcSEcCtD
Buprenorphine—Vomiting—Lisinopril—dilated cardiomyopathy	0.000721	0.00197	CcSEcCtD
Buprenorphine—Rash—Lisinopril—dilated cardiomyopathy	0.000715	0.00196	CcSEcCtD
Buprenorphine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000715	0.00196	CcSEcCtD
Buprenorphine—Headache—Lisinopril—dilated cardiomyopathy	0.000711	0.00195	CcSEcCtD
Buprenorphine—Nausea—Lisinopril—dilated cardiomyopathy	0.000674	0.00184	CcSEcCtD
Buprenorphine—OPRM1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000214	0.00202	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000212	0.00201	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.00021	0.00199	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00021	0.00199	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000206	0.00195	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000205	0.00194	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—SDHA—dilated cardiomyopathy	0.000204	0.00193	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000204	0.00193	CbGpPWpGaD
Buprenorphine—OPRM1—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.000202	0.00192	CbGpPWpGaD
Buprenorphine—OPRK1—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000202	0.00191	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.0002	0.00189	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000198	0.00188	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000193	0.00183	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000193	0.00183	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000191	0.00181	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000191	0.00181	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—ANKRD1—dilated cardiomyopathy	0.000189	0.00179	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000188	0.00178	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000188	0.00178	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000185	0.00175	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000183	0.00174	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000183	0.00173	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000183	0.00173	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000183	0.00173	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000182	0.00172	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—TAZ—dilated cardiomyopathy	0.000178	0.00169	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000178	0.00168	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000176	0.00166	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000174	0.00165	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000172	0.00163	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000171	0.00162	CbGpPWpGaD
Buprenorphine—OPRM1—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000171	0.00162	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.00017	0.00161	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000168	0.00159	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000165	0.00156	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000165	0.00156	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000164	0.00155	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—SDHA—dilated cardiomyopathy	0.000161	0.00152	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000161	0.00152	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000161	0.00152	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ANKRD1—dilated cardiomyopathy	0.000159	0.00151	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000156	0.00147	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—TAZ—dilated cardiomyopathy	0.000151	0.00143	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—TAZ—dilated cardiomyopathy	0.00015	0.00142	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000147	0.00139	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000146	0.00139	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ANKRD1—dilated cardiomyopathy	0.000146	0.00138	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000146	0.00138	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000146	0.00138	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000141	0.00133	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.00014	0.00132	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000139	0.00132	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—TAZ—dilated cardiomyopathy	0.000137	0.0013	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—SDHA—dilated cardiomyopathy	0.000137	0.00129	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000136	0.00129	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000135	0.00128	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—SDHA—dilated cardiomyopathy	0.000135	0.00128	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000134	0.00127	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000132	0.00125	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000132	0.00125	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000132	0.00125	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000131	0.00124	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000129	0.00122	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000129	0.00122	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000128	0.00121	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000128	0.00121	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—SDHA—dilated cardiomyopathy	0.000124	0.00117	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000123	0.00116	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000122	0.00116	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000119	0.00113	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000119	0.00113	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000119	0.00112	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000116	0.0011	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000116	0.0011	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000116	0.0011	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ANKRD1—dilated cardiomyopathy	0.000115	0.00109	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000115	0.00109	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000115	0.00109	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000112	0.00106	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000112	0.00106	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000112	0.00106	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—TAZ—dilated cardiomyopathy	0.000108	0.00102	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000108	0.00102	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000108	0.00102	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000108	0.00102	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000107	0.00101	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000107	0.00101	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000106	0.00101	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000105	0.000991	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000104	0.000989	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000104	0.000982	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000103	0.000979	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000102	0.000964	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000101	0.000956	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.0001	0.000951	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ANKRD1—dilated cardiomyopathy	9.97e-05	0.000944	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—AGT—dilated cardiomyopathy	9.91e-05	0.000938	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	9.9e-05	0.000937	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	9.83e-05	0.00093	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	9.82e-05	0.00093	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	9.81e-05	0.000929	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	9.81e-05	0.000929	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—SDHA—dilated cardiomyopathy	9.79e-05	0.000927	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	9.73e-05	0.000921	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	9.66e-05	0.000914	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	9.56e-05	0.000905	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—TAZ—dilated cardiomyopathy	9.37e-05	0.000887	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	9.32e-05	0.000883	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	9.12e-05	0.000863	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	8.92e-05	0.000845	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ANKRD1—dilated cardiomyopathy	8.9e-05	0.000842	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	8.83e-05	0.000836	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PSEN2—dilated cardiomyopathy	8.81e-05	0.000834	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	8.69e-05	0.000823	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	8.68e-05	0.000822	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	8.61e-05	0.000815	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—SDHA—dilated cardiomyopathy	8.48e-05	0.000803	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8.47e-05	0.000802	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—TAZ—dilated cardiomyopathy	8.37e-05	0.000792	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	8.31e-05	0.000786	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	8.25e-05	0.000782	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	8.18e-05	0.000775	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	8.17e-05	0.000773	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	8.11e-05	0.000768	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—EGFR—dilated cardiomyopathy	7.98e-05	0.000756	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—AGT—dilated cardiomyopathy	7.89e-05	0.000747	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	7.88e-05	0.000746	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CXCL2—dilated cardiomyopathy	7.82e-05	0.00074	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AGTR2—dilated cardiomyopathy	7.82e-05	0.00074	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.72e-05	0.000731	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	7.69e-05	0.000729	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	7.63e-05	0.000722	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—SDHA—dilated cardiomyopathy	7.57e-05	0.000716	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	7.54e-05	0.000714	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—RAC1—dilated cardiomyopathy	7.5e-05	0.00071	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	7.38e-05	0.000699	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.27e-05	0.000688	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	7.24e-05	0.000685	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—AGT—dilated cardiomyopathy	7.16e-05	0.000678	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	7.16e-05	0.000677	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.04e-05	0.000667	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	6.96e-05	0.000659	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	6.93e-05	0.000656	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AGT—dilated cardiomyopathy	6.92e-05	0.000655	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	6.9e-05	0.000653	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—RAF1—dilated cardiomyopathy	6.88e-05	0.000651	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.86e-05	0.000649	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.86e-05	0.000649	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.57e-05	0.000622	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	6.56e-05	0.000622	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PSEN2—dilated cardiomyopathy	6.53e-05	0.000618	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	6.52e-05	0.000617	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.37e-05	0.000603	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AGT—dilated cardiomyopathy	6.28e-05	0.000595	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.17e-05	0.000584	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	6.12e-05	0.000579	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.01e-05	0.000569	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	5.9e-05	0.000558	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AGT—dilated cardiomyopathy	5.84e-05	0.000553	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.79e-05	0.000549	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.79e-05	0.000549	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.7e-05	0.00054	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—RAC1—dilated cardiomyopathy	5.56e-05	0.000526	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—GPX1—dilated cardiomyopathy	5.53e-05	0.000524	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—CD36—dilated cardiomyopathy	5.39e-05	0.00051	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CXCR3—dilated cardiomyopathy	5.39e-05	0.00051	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	5.35e-05	0.000507	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AGT—dilated cardiomyopathy	5.31e-05	0.000503	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.27e-05	0.000499	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.22e-05	0.000494	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	5.17e-05	0.00049	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	5.04e-05	0.000477	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	5.03e-05	0.000476	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ADRB2—dilated cardiomyopathy	5e-05	0.000474	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.97e-05	0.000471	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.9e-05	0.000464	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—AGT—dilated cardiomyopathy	4.85e-05	0.000459	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	4.82e-05	0.000456	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—EGFR—dilated cardiomyopathy	4.72e-05	0.000447	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	4.62e-05	0.000437	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	4.55e-05	0.000431	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	4.53e-05	0.000429	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	4.5e-05	0.000426	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	4.49e-05	0.000426	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.46e-05	0.000422	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—RAC1—dilated cardiomyopathy	4.43e-05	0.000419	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—GPX1—dilated cardiomyopathy	4.37e-05	0.000414	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.36e-05	0.000413	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.3e-05	0.000407	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	4.29e-05	0.000406	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—CD36—dilated cardiomyopathy	4.26e-05	0.000403	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AGT—dilated cardiomyopathy	4.23e-05	0.000401	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.23e-05	0.0004	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	4.21e-05	0.000398	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	4.1e-05	0.000388	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	4.05e-05	0.000383	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—RAC1—dilated cardiomyopathy	3.88e-05	0.000368	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—AGT—dilated cardiomyopathy	3.83e-05	0.000363	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—GPX1—dilated cardiomyopathy	3.71e-05	0.000351	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AGT—dilated cardiomyopathy	3.71e-05	0.000351	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.69e-05	0.000349	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.68e-05	0.000349	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—GPX1—dilated cardiomyopathy	3.68e-05	0.000348	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.63e-05	0.000344	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—CD36—dilated cardiomyopathy	3.61e-05	0.000342	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	3.6e-05	0.00034	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—CD36—dilated cardiomyopathy	3.58e-05	0.000339	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	3.5e-05	0.000332	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.41e-05	0.000323	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—GPX1—dilated cardiomyopathy	3.37e-05	0.000319	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—CD36—dilated cardiomyopathy	3.28e-05	0.000311	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—RAC1—dilated cardiomyopathy	3.28e-05	0.000311	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—AGT—dilated cardiomyopathy	3.25e-05	0.000308	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—AGT—dilated cardiomyopathy	3.22e-05	0.000305	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.15e-05	0.000299	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AGT—dilated cardiomyopathy	3.14e-05	0.000297	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.99e-05	0.000283	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—AGT—dilated cardiomyopathy	2.96e-05	0.00028	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—RAF1—dilated cardiomyopathy	2.94e-05	0.000278	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	2.66e-05	0.000252	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.61e-05	0.000247	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	2.59e-05	0.000245	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—RAF1—dilated cardiomyopathy	2.57e-05	0.000244	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.53e-05	0.000239	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	2.33e-05	0.000221	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GPX1—dilated cardiomyopathy	2.3e-05	0.000218	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CD36—dilated cardiomyopathy	2.24e-05	0.000212	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—RAF1—dilated cardiomyopathy	2.18e-05	0.000206	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GPX1—dilated cardiomyopathy	2.06e-05	0.000195	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AGT—dilated cardiomyopathy	2.02e-05	0.000191	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EGFR—dilated cardiomyopathy	2.01e-05	0.000191	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	2.01e-05	0.00019	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CD36—dilated cardiomyopathy	2e-05	0.00019	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CD36—dilated cardiomyopathy	1.95e-05	0.000185	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	1.89e-05	0.000179	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	1.87e-05	0.000177	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	1.84e-05	0.000174	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	1.83e-05	0.000173	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AGT—dilated cardiomyopathy	1.8e-05	0.000171	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.77e-05	0.000167	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AGT—dilated cardiomyopathy	1.76e-05	0.000167	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	1.66e-05	0.000157	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	1.64e-05	0.000156	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	1.6e-05	0.000152	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	1.56e-05	0.000148	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.49e-05	0.000141	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	1.4e-05	0.000133	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	1.24e-05	0.000117	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	1.2e-05	0.000114	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	1.08e-05	0.000103	CbGpPWpGaD
